1 completed, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow GW Research Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes GWP42003-P - Epilepsy, Dravet Syndrome | Phase 3 | Completed | GW Research Ltd | 681 | 2015-06-11 | 2022-02-03 |
| Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. Sativex, Placebo - Spasticity, Multiple Sclerosis | Phase 3 | Withdrawn | GW Research Ltd | 2016-08-11 |
Epilepsies, Myoclonic (1) · Epilepsy (1) · Lennox Gastaut Syndrome (1) · Multiple Sclerosis (1) · Muscle Spasticity (1)
Cannabidiol (1) · nabiximols (1)
2014 (1)